Hepatocellular carcinoma (HCC) is one of the most aggressive cancers worldwide. Identification of the molecular mechanisms underlying the development and progression of HCC is particularly important. Here, we demonstrated the expression pattern, clinical significance, and function of Karyopherin α2 (KPNA2) in HCC. The expression of KPNA2 was upregulated in tumor tissue and negatively associated with the survival time, and a significant correlation between KPNA2 expression and aggressive clinical characteristics was established. Both in vitro and in vivo experiments demonstrated that knockdown of KPNA2 reduced migration and proliferation capacities of HCC cells, while over-expression of KPNA2 increased these malignant characteristics. The analysis of the Cancer Genome Atlas cohorts also reveals that high-KPNA2 expression is associated with poor outcome in multiple cancer types. In addition, gene sets enrichment analysis exhibited cell cycle and DNA replication as the top altered pathways in the high-KPNA2 expression group in HCC and other two cancer types. Overall, this study identified KPNA2 as a potential diagnostic and prognostic biomarker in HCC and other neoplasms, probably by regulating cell cycle and DNA replication.
Introduction
Hepatocellular carcinoma (HCC) is the fifth common cancers and one of the leading causes of cancer-related death worldwide [1] . The prognosis of HCC is poor, partly because of its highly aggressive property, 70%-100% of patients with HCC develop recurrence rapidly after hepatectomy, which contributes to the cause of death in 82.5% of the patients [2] . HCC also exhibits more complex intratumoral heterogeneity than other types of tumors, which greatly impairs the efficacy of target therapy in HCC [3] . Thus, it raises the need to clarify the molecular mechanism underlying the carcinogenic progress in HCC, which may hold the promise of identifying more biomarker for HCC diagnosis, prognosis and target therapy.
Karyopherin α2 (KPNA2) belongs to the karyopherin family, which plays a crucial role in nucleocytoplasmic transport [4] . Cooperating with importin-β, KPNA2 mediates numerous nuclear translocations of target proteins guided by nuclear localization signal passing through the nuclear pore complex [5] . Upregulation of KPNA2 has been demonstrated to be associated with various types of cancer, including breast cancer [6] , lung cancer [7] , gastric cancer [8] , colon cancer [9] , prostate cancer [10] , and upper tract urothelial carcinoma [11] . In addition, a previous study showed that upregulation of KPNA2 might promote epithelial ovarian carcinoma cell proliferation and tumorigenicity by enhancing c-Myc and inhibiting FOXO3a transactivation activity [12] . In HCC, Yoshitake et al. [13] reported that KPNA2 is a prognostic marker according to microarray profiles study, however, the prognostic value and potential molecular evidence and mechanisms of KPNA2 in HCC still remains largely unknown.
In this study, we demonstrated KPNA2 as a potential diagnostic and prognostic marker in HCC. Comparative analysis revealed that KPNA2 expression level was closely correlated with important clinicopathological features of HCC. Functional studies of KPNA2 demonstrated that knockdown of KPNA2 could inhibit the proliferation and migration of HCC cells. We further evaluated the prognostic significance of KPNA2 expression across other human cancer types by using The Cancer Genome Atlas (TCGA) database. Higher KPNA2 expression was also significantly associated with poor outcome in other cancer types. Gene sets enrichment analysis (GSEA) revealed that cell cycle and DNA replication-associated genes were altered the most under the changes of KPNA2 expression.
Materials and Methods

Patients and samples
Written informed consent was obtained from each patient, and this study was approved by the Eastern Hepatobiliary Surgery Hospital Research Ethics Committee. In our study, 60 patients who underwent curative hepatectomy at the Eastern Hepatobiliary Surgery Hospital (Shanghai, China) from January 2009 to September 2012 were randomly selected for analysis.
RNA extraction and real-time PCR
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, USA) according to the manufacturer's protocol. RNA quality and quantity were evaluated by Nanodrop 2000 (Thermo Scientific, Waltham, USA), and first-strand cDNA was synthesized from 2 μg of total RNA using random primers and M-MLV Reverse Transcriptase (Invitrogen). Expression of candidate genes was evaluated using real-time polymerase chain reaction (qRT-PCR) performed using an ABI PRISM 7900 sequence detector (Applied Biosystems, Carlsbad, USA) and SYBR Green PCR kit (TaKRa, Kusatsu, Japan). Primers used in our research are listed in Table 1 . Each sample was tested in duplicate, and the relative mRNA expressions were calculated based on the Ct values and were normalized by 18S rRNA expression.
Cell culture and transfection
Liver cancer cell lines PLC/PRF/5 and HCC-LM3 were purchased from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Cell lines were maintained at 37°C in an atmosphere containing 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco, Carlsbad, USA). To regulate KPNA2 expression in vitro, siRNA or KPNA2-overexpressing plasmid (Biotend, Shanghai, China) was transfected into PLC/PRF/5, or HCC-LM3 with Lipofectamine 2000 (Invitrogen). Briefly, siRNA or plasmid and Lipo2000 were incubated with Opti-MEM (Invitrogen) for 5 min separately, and then mixed together for 20 min at room temperature. The mixture was then applied to the cells plated in 6-cm dishes (with a final concentration of 50-nM siRNA). The siRNA sense sequence is: UUGACCUCUAUUCUGCGACdTdT. SiRNA-control (UUCUCCG AACGUGUCACG) was used as a negative control.
Western blot analysis
Total protein was extracted using RIPA lysis buffer and PMSF (Thermo Scientific) according to the manufacturer's instructions, and centrifuged at 13,800 g for 15 min. Protein concentrations were measured using the bicinchoninic acid assay. Protein samples were subject to SDS-PAGE and then transferred to PVDF membranes (Millipore, Billerica, USA). Antibody dilutions were 1:500 for the anti-KPNA2 antibody (Abcam, Cambridge, USA) and 1:10,000 for the anti-GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, USA). After incubation with primary antibodies, membranes were extensively washed and then incubated with the fluorescein-conjugated secondary antibody (Therm Scientific). Finally, antibody binding was detected with an Odyssey infrared scanner (Li-CorBiosciences, Lincoln, USA.)
Cell migration, invasion, and proliferation analysis Migration was performed using the transwell filter chambers (Costar, Corning, USA) according to the manufacturer's instructions. Briefly, 1 × 10 5 cells were suspended in serum-free medium, and added into the top chamber. Medium with 10% FBS was added to the lower chamber. After 12 h of incubation, cells on the lower surface of the membrane were stained, photographed, and counted using a microscope in six random fields per field for each group. For invasion assay, the porous filter is overlaid by a thin layer of ECM, before cells were seeded into the top chamber. The ECM occludes the membrane pores, blocking non-invasive cells from migrating. These experiments were performed in triplicate. For proliferation assay, cells were seeded into 96-well plates (3000/well), and cell viability was determined using Cell Counting Kit8 (APExBIO Dojindo Laboratories, Houston, USA) every 24 h. 
In vivo xenograft experiment HCC-LM3 and PLC/PRF/5 (1 × 10 6 cells) cells were subcutaneously injected into the nude mice (6 weeks old, n = 3), respectively. After 2 weeks, the mice were sacrificed and the tumor mass were extracted and photographed. Nude mice were from the Shanghai Experimental Animal Center (Shanghai, China).
TCGA data processing and data analysis KPNA2 mRNA expression levels, TP53 mutations and clinical information in each TCGA study were downloaded from cBioPortal (http://www.cbioportal.org/data_sets.jsp) [14] . Two groups were divided according to the median expression level of each gene. Survival differences among groups were estimated using the R package 'survival'. Kaplan-Meier plots were constructed and a log-rank test was used to determine differences among overall survival according to the KPNA2 mRNA levels in HCC and other cancer types. The receiving operating character (ROC) curve were calculated and drawn with R package 'POCR'. The difference between KPNA2 mRNA expression levels and different status of TP53 mutation was analyzed by Mann-Whitney U test using the R software (http://www.r-project.org/) functions wilcox.test. GSEA was performed by the JAVA program (http://www.broadinstitute.org/gsea) using MSigDB C2 CP: KEGG gene sets collection (186 gene sets available) [15] . Gene sets with a false discovery rate (FDR) value <0.05 after performing 1000 permutations were considered to be significantly enriched.
Results
KPNA2 is upregulated in hepatocellular carcinoma
KPNA2-expression level was measured in 60 paired solid tumor tissues and non-tumor liver tissues by qRT-PCR. KPNA2 mRNA level was significantly higher in HCC tumors than that in non-tumor liver samples (Fig. 1A) . This finding was further validated using our previous study of illumina RNA sequence result (GSE77314) upon 50 pairs of normal and tumor samples (Fig. 1B) . External validation was done using TCGA liver cancer cohorts (Fig. 1C) . These results demonstrated that KPNA2 expression was upregulated in HCC.
A receiver operating characteristic curve (ROC curve) is a graphical plot that illustrates the diagnostic ability of a system. Here, ROC curve analysis was used to evaluate the sensitivity and specify of KPNA2 as a diagnostic marker. The area under curve (AUC) was calculated to determine the diagnostic value of KPNA2. In qRT-PCR, GSE77314 and TCGA cohort, AUC reached 0.731, 0.986, and 0.895, respectively (Fig. 1D-F) . Taken together, these results suggested that KPNA2 may be a valuable marker for HCC diagnosis.
Upregulation of KPNA2 is associated with poor prognosis of hepatocellular carcinoma
We further investigated if the KPNA2 has prognostic value in HCC using Kaplan-Meier survival methods and log-rank test. HCC patients were divided into two groups, i.e. high-KPNA2 expression group and low-KPNA2 expression group, in each dataset by using median of KPNA2 expression level as the cutoff. It was found that the survival time of patients in the high-KPNA2 expression group was significantly shorter than the survival time of patients with low-KPNA2 expression, with log-rank P to be 0.00025, 0.041, and <0.0001, respectively, for the qRT-PCR, GSE77314, and TCGA cohorts ( Fig. 2A-C) . These results supported KPNA2 as a prognostic marker for HCC. It was also noticed that the expression of KPNA2 was significantly higher in patients with high-metastatic potential than those with low-metastatic potential in the qRT-PCR cohorts (37 with low metastasis and 18 with high metastasis; Fig. 2D ). The association between high-KPNA2 expression and high-metastatic potential was confirmed in GSE77314 (Fig. 2E) . Upregulation of the KPNA2 expression is associated with worse HCC histologic grade, and KPNA2 expression was found to be closely correlated with histologic grade of 373 HCC patients from the TCGA cohort (Fig. 2F) . Thus, the above results indicated that KPNA2 might play pro-metastatic and pro-malignant roles in HCC. Figure 2 . The prognostic value of KPNA2 in HCC Patients with high-expression level of KPNA2 has a relatively poor overall survival rate according to the results from qRT-PCR (A), GSE77314 (B) and TCGA (C). The KPNA2 mRNA expression level in high-metastasis patients is significantly higher than that in lowmetastasis patients in our qRT-PCR cohort (D) and GSE77314 cohort (E). The KPNA2 expression level is associated with HCC histologic grade in TCGA (F). FPKM: Fragments Per Kilobase of transcript per Million mapped reads; LMG, low-metastasis group; HMG, high-metastasis group.
The correlation of KPNA2 expression with clinical characteristics
The correlation between corresponding clinical information and gene expression of KPNA2 were analyzed. As shown in Table 2 (Fisher's exact test), important classic clinical features were associated with KPNA2 mRNA level. Overall, recurrence was detected in 52.4% (11/21) patients in the high-KPNA2 expression group, while only 13% (3/23) patients in the low-KPNA2 expression group experienced recurrence (odds ratio: 4.3, P = 0.02). Moreover, 93.5% (29/31) patients in the high-KPNA2 expression group were highly differentiated, in contrast to 34.5% (10/29) in the low-KPNA2 expression group (odds ratio: 2.71, P = 0.09). When the primary tumor stage was evaluated, 41.9% (13/31) patients were at T3 and T4 stage in the high-KPNA2 expression group, while only 3.4% (1/29) patients exhibited T3 and T4 stage in the low-KPNA2 expression group (odds ratio: 12.2, P = 0.0005). Portal vein tumor thrombus is an important indicator of metastasis. In the high-KPNA2 expression group, tumor thrombi in the portal vein were detected in 46.7% (14/30) patients, but in the low-KPNA2 expression group only one patient out of 28 (odds ratio: 14.5, P = 0.0002) was detected. In addition, other clinical observations including microvascular embolus (P = 2.5 × 10 −6 ) and AFP (P = 0.006) levels were also significantly correlated with KPNA2 expression levels. All the above results suggest that KPNA2 correlates with important clinicopathologic indicators and may be a proliferation-and metastasisrelated factor in HCC.
KPNA2 expression regulates malignant characteristics of HCC cell lines
Immunohistochemistry staining of KPNA2 revealed that KPNA2 was upregulated in HCC tumors compared with its normal liver tissue (Fig. 3A) . Functional studies were performed to evaluate the role of KPNA2 in two different HCC cell lines, MHCC-LM3 and PLC/ PRF/5. KPNA2 was silenced using siRNAs and upregulated by using KPNA2-overexpressing plasmid (Fig. 3B,C) , and its impact on cell proliferation was assessed by CCK8 assay. Compared with control cell lines, the OD 450 value of siKPNA2 groups was significantly lower, while the level was higher in the overexpression group, indicating that KPNA2 modulates the proliferation of HCC cells (Fig. 3D,E) . Recent studies also indicated that high expression of KPNA2 was correlated with microvascular embolus and portal vein tumor thrombus, thus we further assessed the effect of KPNA2 on cell migration and invasion using transwell assay. After 48 h, siKPNA2 inhibited cell migration and invasion compared with the control group, meanwhile, KPNA2 overexpression promoted cell migration and invasion (Fig. 3F,G) , in both MHCC-LM3 and PLC/PRF/5 cell lines, implying that KPNA2 may have an impact on metastasis of HCC cells. In vivo xenograft experiment consistently confirmed that overexpression of KPNA2 in HCC-LM3 and PLC/PRF/5 cells increased its tumorigenesis in nude mice, while knockdown of KPNA2 weakened its malignant characteristics (Fig. 3H,I ).
KPNA2 has prognostic value across human cancer types
The prognostic value of KPNA2 expression in other human cancer types was evaluated using Kaplan-Meier analyses and log-rank test. Elevation of KPNA2 mRNA expression is significantly associated with shorter overall survival time in multiple cancer types. For example, renal clear cell carcinoma (Fig. 4A) , lung adenocarcinoma (Fig. 4B) , and skin cutaneous melanoma (Fig. 4C) exhibited significant differences in survival time between high-KPNA2 expression group and low-KPNA2 expression group. Along with the results from previous studies of breast [6] and bladder cancer [16] , these findings indicated that KPNA2 might function as tumor oncogene in various human cancer types.
Potential molecular mechanisms of KPNA2 in carcinogenesis and malignancy
To investigate the potential signaling pathway that may contribute to KPNA2-mediated proliferation and metastasis of HCC cells, we carried out GSEA. Patients in TCGA liver cancer cohort were divided into high-KPNA2 expression group and low-KPNA2 expression group, based on the median mRNA expression level of KPNA2. Gene sets enrichment analysis was performed with GSEA (http://www.broadinstitute.org/gsea). It was found that cell cycle, DNA replication, homologous recombination, p53 signaling, mismatch repair, and spliceosome pathway were significantly enriched in the high-KPNA2 expression group (Fig. 5A) . Of these, cell cycle and DNA replication were the top two significantly enriched gene sets and most genes enriched in these pathways were elevated in the high-KPNA2 expression group (Fig. 5B,C) , suggesting that the change in KPNA2 expression level might activate cell cycle-related The high-KPNA2 expression group and low-KPNA2 expression group are defined based on median mRNA expression value of KPNA2. a Some clinical information is missing. *P < 0.05 by χ 2 test.
pathways. So, we further tested the expressions of cyclin B2, PCNA, CDK1, c-Myc as the representative factors in cell cycle, and DNA replication-related pathway by qRT-PCR. Consistent with the GSEA, expressions of these factors were found to be changed with the KPNA2 expression, confirming that KPNA2 expression could activate cell cycle and DNA replication pathways ( Supplementary Fig. S1 ). We also performed GSEA among TCGA breast cancer (Fig. 5D-F ) and lung adenocarcinoma ( Fig. 5G-I ) cohorts. Similar results were obtained in breast cancer and lung adenocarcinoma, with cell cycle and DNA replication as the top two significantly enriched pathways in the high-KPNA2 expression group, indicating the important role KPNA played across different types of neoplasms. 
Discussion
Alterations in the cellular transport machinery commonly occur in cancer cells and are associated with tumorigenesis and tumor progression [17] . Nuclear transporters play a crucial role in regulating the pathological development of cancers. Kpnβ1, a nuclear import protein was reported as an antitumor target in cervical cancer [18] . Furthermore, Yang et al. [19] showed that the expression of Kpnβ1 was upregulated in HCC and Kpnβ1 might serve as a contributing factor in HCC via the NF-кB signaling pathway and serve as an independent prognostic indicator and a novel therapeutic target for To further investigate the potential mechanism underlying KPNA2-mediated migration and proliferation, we performed KEGG pathway enrichment analysis to evaluate differentially expressed genes between high-KPNA2 expression group and low-KPNA2 expression group. Our results indicated that the top two significantly affected pathways were the cell cycle pathway and DNA replicated pathway, which was also consistent with our functional finding in vitro. Winkler et al. [20] reported that the regulation of KPNA2 by p53 requires the induction of the cyclin-dependent kinase inhibitor p21, and reduced KPNA2 could induce p53 and p21, which plays a central role in the regulation of nuclear DNA replication, homologous recombination, and other processes of cell cycle. Hence Winkler's finding might explain the role of KPNA2 in HCC and is consistent with our findings in KEGG pathway enrichment analysis. Interestingly, the gene sets enrichment analysis in breast cancer and lung adenocarcinoma cohorts of TCGA showed similar result as in HCC, which suggests that KPNA2 might play similar roles in these cancers [21] . However, further studies are needed to confirm whether KPNA2 is a pan-anticancer target in cancers.
Primary liver cancer is one of the most fatal malignancies which accounts for the third cancer-related death worldwide. And HCC is the most common pathology type in primary liver cancer. Surgical procedure still remains the only curative method in HCC treatment, however, it is only suitable in early-stage disease. Hence, developing novel treatment is of great urgency for the benefit of HCC patients. Our study demonstrated that KPNA2 has great potential to be a diagnostic and prognostic marker. KPNA2 might affect HCC cell proliferation and migration by mediating cell cycle and DNA replication pathway, which suggests that it could serve as a promising therapeutic target for HCC in the future.
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